A rapidly escalating Ebola Bundibugyo virus outbreak in Central and East Africa has ignited a sharp international dispute between the United States and the World Health Organization — one that is reopening deep wounds from the COVID-19 pandemic. As of mid-May 2026, the Ebola outbreak has resulted in over 500 suspected cases and more than 130 deaths. The World Health Organization declared the current outbreak, specifically the Bundibugyo virus, a public health emergency of international concern on May 16. In response to the outbreak, the Trump administration invoked Title 42 to restrict entry for non-US passport holders who have been in the DRC, South Sudan, and Uganda in the previous 21 days, with the ban set to be in effect for at least 30 days.
Rubio's Broadside: 'WHO Failed Miserably During COVID'
US Secretary of State Marco Rubio did not hold back when confronted with questions about America's unilateral approach to the outbreak. "The WHO, unfortunately, has not performed well globally. I think it failed miserably during COVID, covering up for China," Rubio said — while simultaneously leaving the door open to working with the agency: "We will work with anyone who wants to fix that issue." Rubio had earlier declared that the US lead on the Ebola response would fall to the Centers for Disease Control and Prevention (CDC) and the WHO, "which was a little late to identify this thing unfortunately." He said the US had committed roughly $13 million and hoped to open "around 50 clinics" in what he called "hard-to-get-to places in a war-torn country."
The WHO Director-General pushed back firmly. WHO Director-General Tedros Adhanom Ghebreyesus responded that Rubio's critique might stem from a "lack of understanding" of the International Health Regulations, stressing that "we don't replace the country's work — we only support them." WHO officials noted that the agency was alerted on May 5 and sent a team to Ituri, but initial tests came back negative because the region's diagnostics were designed for the far more common Zaire strain of Ebola, not the Bundibugyo strain now circulating. Samples then had to travel some 1,700 kilometres to a laboratory in Kinshasa, which confirmed Bundibugyo on May 14. For WHO's official outbreak tracking data, case counts, and IHR recommendations on the current Ebola emergency, the World Health Organization's Disease Outbreak News portal is updated continuously by WHO field teams across the affected regions.
The Science vs. The Policy: Is the Travel Ban Justified?
The US travel restrictions have put Washington on a collision course with the global health community's established consensus. According to WHO officials, the ban is not recommended as Ebola is not an airborne virus — it spreads only through direct contact with blood or body fluids — meaning travel restrictions are "not supported under the IHR recommendations." The WHO's position has been consistent across previous outbreaks: travel bans tend to discourage transparency from affected countries, impede the movement of response workers and supplies, and create false perceptions of safety without meaningfully reducing transmission risk in destination countries.
Rubio's counter-argument is political and precautionary rather than epidemiological. His position reflects a broader Trump administration philosophy that leans heavily on border controls as a primary public health instrument — consistent with the administration's approach to COVID-19, fentanyl, and illegal immigration. An American doctor, Peter Stafford, whose family lived with him in the DRC, was confirmed positive for Ebola and evacuated to Germany for treatment — the first American national known to be infected in the current outbreak, providing a concrete trigger for Washington's precautionary posture. For the administration, the question is not whether Ebola is airborne; it is whether even a low probability of an imported case in the US is acceptable given the alternatives.
America's Complicated History With Ebola Travel Bans
The current debate has a direct historical antecedent that Rubio himself was part of. During the 2014 West Africa Ebola outbreak — which ultimately killed more than 11,000 people — Rubio, then a senator, introduced legislation to ban new US visas for people from Liberia, Guinea, and Sierra Leone, saying "our biggest priority is ensuring that sufficient safeguards are in place to limit the spread of Ebola, contain it at the source, and protect Americans." The Obama administration resisted that approach, opting instead for enhanced airport screening, and the outbreak was ultimately contained without the travel restrictions Rubio had sought. The 2026 outbreak has given him a second opportunity to implement the policy he advocated twelve years ago — this time from inside the executive branch.
US Aid Cuts and the Surveillance Gap: The Backstory Nobody Wants to Discuss
The WHO confined its response to Rubio to narrow procedural grounds. It could not explain why the diagnostic and surveillance capacity that might have identified Bundibugyo weeks earlier had been so degraded, nor who was responsible. The answer that neither Rubio nor the WHO publicly addressed is that US foreign aid cuts — implemented in the first months of the Trump administration through USAID restructuring — eliminated several community health surveillance and laboratory network programmes in the DRC and Uganda that had been jointly funded by the US and WHO. The very surveillance gap that delayed Bundibugyo identification is, at least in part, a consequence of the policy environment the administration itself created. The irony is stark: the US is defending a travel ban as a response to an outbreak whose early detection was hampered by cuts the same administration made to the global health infrastructure designed to catch precisely these events early.
What Comes Next
As of the WHO's media briefing on May 21, 51 cases had been confirmed in the DRC, alongside almost 600 suspected cases and 139 suspected deaths, with Uganda reporting two confirmed cases in the capital Kampala including one death. The 30-day Title 42 travel restriction will be reviewed as the outbreak evolves. If case counts continue climbing and spread accelerates into additional countries, the administration is likely to expand the ban rather than lift it. For investors watching the biodefence and diagnostics sector, the outbreak has already triggered a surge in interest in companies working on broad-spectrum filovirus detection platforms — a reminder that public health crises and geopolitical disputes over global health governance are now inextricably linked investment themes for 2026 and beyond.